€20.40
Your prediction
Intellia Therapeutics Inc Stock
Pros and Cons of Intellia Therapeutics Inc in the next few years
Pros
Cons
Performance of Intellia Therapeutics Inc vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Intellia Therapeutics Inc | -0.680% | 9.957% | -2.930% | -36.191% | -29.050% | -84.666% | 53.398% |
Chromadex Corp | 3.130% | 4.430% | 12.245% | 150.000% | 150.000% | -37.143% | -12.733% |
Organovo Holdings Inc. | 1.090% | -6.818% | -16.327% | -67.366% | -56.043% | -93.040% | -91.136% |
Polynovo Ltd | -3.290% | -2.000% | -3.922% | 96.000% | 47.739% | 20.492% | 6.491% |
Comments
News
The Bull Case for Intellia Therapeutics Stock Just Got Even Stronger
Intellia Therapeutics (NASDAQ: NTLA) just published some new data that suggests the company has what it takes to continue being a leader in the gene editing space. While there's still a lot of work
Cathie Wood Goes Bargain Hunting: 2 Stocks She Just Bought
Cathie Wood is known for two things: picking out innovators that will go on to score a win over the long run, and getting in on these stocks at a great price. The founder and chief executive officer
These 2 Words Are Why Intellia Therapeutics Could Be a Smart Buy Right Now
On June 2, Intellia Therapeutics' (NASDAQ: NTLA) CEO John Leonard remarked on the biotech's progress with one of its early-stage clinical programs called NTLA-2002, uttering two very important words